These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19601823)

  • 1. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitigating permeability-mediated risks in drug discovery.
    Wang J; Skolnik S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.
    Wang J; Urban L; Bojanic D
    Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):641-65. PubMed ID: 17916053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing the outcome of early ADMET models: strategies to win the drug-hunting battles?
    Wang J; Collis A
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):381-6. PubMed ID: 21417818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico ADMET prediction: recent advances, current challenges and future trends.
    Cheng F; Li W; Liu G; Tang Y
    Curr Top Med Chem; 2013; 13(11):1273-89. PubMed ID: 23675935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules.
    Khan MT; Sylte I
    Curr Drug Discov Technol; 2007 Oct; 4(3):141-9. PubMed ID: 17985997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical formulations: insight, strategies, and practical considerations.
    Shah SM; Jain AS; Kaushik R; Nagarsenker MS; Nerurkar MJ
    AAPS PharmSciTech; 2014 Oct; 15(5):1307-23. PubMed ID: 24920522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery.
    Lin J; Sahakian DC; de Morais SM; Xu JJ; Polzer RJ; Winter SM
    Curr Top Med Chem; 2003; 3(10):1125-54. PubMed ID: 12769713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of preformulation on drug development.
    Bharate SS; Vishwakarma RA
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1239-57. PubMed ID: 23534681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro approaches to evaluate ADMET drug properties.
    Li AP
    Curr Top Med Chem; 2004; 4(7):701-6. PubMed ID: 15032683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery today.
    Schwardt O; Kolb H; Ernst B
    Curr Top Med Chem; 2003; 3(1):1-9. PubMed ID: 12570684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE; Landrum GA; Putta S
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.